scroll to top
0

Mobile Menu

Header Layout

EBSCO Auth Banner

Let's find your institution. Click here.

Page title

Advanced Search Results For "HYPERTENSION"

1 - 10 of 568,092 results for
 "HYPERTENSION"
Results per page:

Porto-pulmonary arterial hypertension: Translation of pathophysiological concepts to the bedside.

Publication Type:Academic Journal

Source(s):Vascular pharmacology [Vascul Pharmacol] 2022 Aug; Vol. 145, pp. 107022. Date of Electronic Publication: 2022 Jun 20.

Abstract:Porto-pulmonary arterial hypertension (PoPAH) is a form of pulmonary arterial hypertension (PAH) that affects patients with cirrhosis, and - to a lesser extent - patients with non-cirrhotic liver diseases. Compared with other forms of PAH, PoPAH is mor...

View details

Decoding the Link Between Inflammation and Pulmonary Arterial Hypertension.

Publication Type:Editorial & Opinion

Source(s):Circulation [Circulation] 2022 Sep 27; Vol. 146 (13), pp. 1023-1025. Date of Electronic Publication: 2022 Sep 26.

View details

Regnase-1 Prevents Pulmonary Arterial Hypertension Through mRNA Degradation of Interleukin-6 and Platelet-Derived Growth Factor in Alveolar Macrophages.

Publication Type:Academic Journal

Source(s):Circulation [Circulation] 2022 Sep 27; Vol. 146 (13), pp. 1006-1022. Date of Electronic Publication: 2022 Aug 23.

Abstract:Background: Pulmonary arterial hypertension (PAH) is a type of pulmonary hypertension (PH) characterized by obliterative pulmonary vascular remodeling, resulting in right-sided heart failure. Although the pathogenesis of PAH is not fully understood, in...

View details

Twenty-Year Experience and Outcomes in a National Pediatric Pulmonary Hypertension Service.

Publication Type:Academic Journal

Source(s):American journal of respiratory and critical care medicine [Am J Respir Crit Care Med] 2022 Sep 15; Vol. 206 (6), pp. 758-766.

Abstract:Rationale: Pediatric pulmonary hypertension is an important cause of childhood morbidity and mortality, but there are limited data on the range of associated diseases, contributions of different pulmonary hypertension subtypes, therapeutic strategies, ...

View details

Microrna-486-5P Regulates Human Pulmonary Artery Smooth Muscle Cell Migration via Endothelin-1.

Publication Type:Academic Journal

Source(s):International journal of molecular sciences [Int J Mol Sci] 2022 Sep 08; Vol. 23 (18). Date of Electronic Publication: 2022 Sep 08.

Abstract:Pulmonary arterial hypertension (PAH) is a fatal or life-threatening disorder characterized by elevated pulmonary arterial pressure and pulmonary vascular resistance. Abnormal vascular remodeling, including the proliferation and phenotypic modulation o...

View details

Novel insights into the association between seasonal variations, blood pressure, and blood pressure variability in patients with new-onset essential hypertension.

Publication Type:Academic Journal

Source(s):BMC cardiovascular disorders [BMC Cardiovasc Disord] 2022 Sep 08; Vol. 22 (1), pp. 401. Date of Electronic Publication: 2022 Sep 08.

Abstract:Background: Blood pressure (BP) exhibits seasonal variations, with peaks reported in winter. However, the association between seasonal variations and blood pressure variability in patients with new-onset essential hypertension is not fully understood. ...

View details

Clinical Characteristics of Patients Undergoing Right Heart Catheterizations in Community Hospitals.

Publication Type:Academic Journal

Source(s):Journal of the American Heart Association [J Am Heart Assoc] 2022 Sep 06; Vol. 11 (17), pp. e025143. Date of Electronic Publication: 2022 Sep 05.

Abstract:Background Recognition of precapillary pulmonary hypertension (PH) has significant implications for patient management. However, the low a priori chance to find this rare condition in community hospitals may create a barrier against performing a right ...

View details

Molecular Pathways in Pulmonary Arterial Hypertension.

Publication Type:Academic Journal

Source(s):International journal of molecular sciences [Int J Mol Sci] 2022 Sep 02; Vol. 23 (17). Date of Electronic Publication: 2022 Sep 02.

Abstract:Pulmonary arterial hypertension is a multifactorial, chronic disease process that leads to pulmonary arterial endothelial dysfunction and smooth muscular hypertrophy, resulting in impaired pliability and hemodynamics of the pulmonary vascular system, a...

View details

Hispanic Ethnicity and Social Determinants of Health in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry.

Publication Type:Academic Journal

Source(s):Annals of the American Thoracic Society [Ann Am Thorac Soc] 2022 Sep; Vol. 19 (9), pp. 1459-1468.

Abstract:Rationale: There is a noticeable underrepresentation of minorities in clinical trials and registries in pulmonary arterial hypertension (PAH). Prior studies evaluating the association between Hispanic ethnicity and clinical outcomes in patients with PA...

View details

Prognostic Value of Echocardiographic Variables Prior to and Following Initiation of Parenteral Prostacyclin Therapy: An Observational Study.

Publication Type:Academic Journal

Source(s):Chest [Chest] 2022 Sep; Vol. 162 (3), pp. 669-683. Date of Electronic Publication: 2022 Apr 20.

Abstract:Background: Echocardiographic parameters are used as prognostic markers in patients with pulmonary arterial hypertension (PAH) receiving parenteral (IV or subcutaneous [IV/SC]) prostacyclin therapy. However, data on how posttreatment echocardiographic ...

View details

banner_970x250 (970x250)

sponsored